Transthyretin Amyloid Cardiomyopathy Transthyretin Amyloid Cardiomyopathy (ATTR heart disease)
Conditions
Interventions
Acoramidis 
(Beyonttra)
Sponsors
Bayer
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adults (=18 years at the date of signing the informed consent form (ICF)).Diagnosis of either wild-type or variant ATTR-CM.Signed ICF.Decision to initiate treatment with acoramidis was made as per treating investigator’s routine treatment practice before signature of ICF.Treatment initiation with acoramidis within 90 days after signing the ICF, with the possibility of starting acoramidis on the same day as signing the ICF.
Exclusion criteria
Exclusion criteria: Participation in an investigational trial with interventions outside of routine clinical practice, except for participation in potential sub-studies related to this observational study.Contra-indications according to the local SmPC of acoramidis.Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess characteristics and treatment patterns of ATTR-CM patients initiating acoramidis. | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the reported safety profile of acoramidis. | — |
Countries
Austria, Belgium, Croatia, Denmark, Estonia, Finland, Germany, Greece, Ireland, Italy, Latvia, Luxembourg, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Contacts
Public ContactE.J. Koning
Bayer
Outcome results
None listed